Concepedia

Stephen Antonysamy

SA

Statistics

Publications

17

Citations

1.7K

H-Index

16

Active since

2005

Affiliations

Eli Lilly (United States)(Current)

Princess Margaret Cancer Centre

University of Toronto

Structural Genomics Consortium

Argonne National Laboratory

Stephen Antonysamy is an author at Eli Lilly (United States) specializing in medicinal chemistry, drug discovery, and life sciences.

Publications per year

2005–2024

17

Publications

17

Crystal structure of the human PRMT5:MEP50 complex

Stephen Antonysamy, Zahid Bonday, Robert M. Campbell et al. · Proceedings of the National Academy of Sciences · 2012 · 363 citations · Full text

, , +17

Structural analysis of a set of proteins resulting from a bacterial genomics project

John Badger, J.M. Sauder, J.M. Adams et al. · Proteins Structure Function and Bioinformatics · 2005 · 249 citations

, , +15

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor Gene

Xueqian Gong, Jian Du, Stephen H. Parsons et al. · Cancer Discovery · 2018 · 233 citations

, , +17

LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity

Zahid Bonday, Guillermo S. Cortez, Michael J. Grogan et al. · ACS Medicinal Chemistry Letters · 2018 · 181 citations · Full text

, , +8

LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2

Hannah Nguyen, Abdellah Allali‐Hassani, Stephen Antonysamy et al. · Journal of Biological Chemistry · 2015 · 131 citations · Full text

, , +11

1–5 of 17